AU667327B2 - Composition and method of treating hepatitis C - Google Patents
Composition and method of treating hepatitis C Download PDFInfo
- Publication number
- AU667327B2 AU667327B2 AU26447/92A AU2644792A AU667327B2 AU 667327 B2 AU667327 B2 AU 667327B2 AU 26447/92 A AU26447/92 A AU 26447/92A AU 2644792 A AU2644792 A AU 2644792A AU 667327 B2 AU667327 B2 AU 667327B2
- Authority
- AU
- Australia
- Prior art keywords
- thymosin
- interferon
- hepatitis
- international
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 208000005176 Hepatitis C Diseases 0.000 title claims description 24
- 239000000203 mixture Substances 0.000 title claims description 19
- 102000007501 Thymosin Human genes 0.000 claims abstract description 67
- 108010046075 Thymosin Proteins 0.000 claims abstract description 67
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims abstract description 50
- 102000014150 Interferons Human genes 0.000 claims description 52
- 108010050904 Interferons Proteins 0.000 claims description 52
- 229940079322 interferon Drugs 0.000 claims description 52
- 238000011282 treatment Methods 0.000 claims description 48
- 241000711549 Hepacivirus C Species 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 17
- 229940047124 interferons Drugs 0.000 claims description 13
- 208000006454 hepatitis Diseases 0.000 claims description 12
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 12
- 231100000283 hepatitis Toxicity 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 8
- 230000003389 potentiating effect Effects 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 241000282577 Pan troglodytes Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 abstract 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 abstract 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
- 229960004231 thymalfasin Drugs 0.000 abstract 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 29
- 108010082126 Alanine transaminase Proteins 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 21
- 230000004044 response Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000012317 liver biopsy Methods 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- -1 TF-5 Chemical compound 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000008935 histological improvement Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001785 maturational effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75954491A | 1991-09-13 | 1991-09-13 | |
| US759544 | 1991-09-13 | ||
| PCT/US1992/007556 WO1993005806A1 (en) | 1991-09-13 | 1992-09-08 | Composition and method of treating hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2644792A AU2644792A (en) | 1993-04-27 |
| AU667327B2 true AU667327B2 (en) | 1996-03-21 |
Family
ID=25056052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU26447/92A Ceased AU667327B2 (en) | 1991-09-13 | 1992-09-08 | Composition and method of treating hepatitis C |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6001799A (OSRAM) |
| EP (1) | EP0603305B1 (OSRAM) |
| JP (1) | JP3228512B2 (OSRAM) |
| KR (1) | KR100254082B1 (OSRAM) |
| AT (1) | ATE152914T1 (OSRAM) |
| AU (1) | AU667327B2 (OSRAM) |
| CA (1) | CA2119006C (OSRAM) |
| CZ (1) | CZ286827B6 (OSRAM) |
| DE (1) | DE69219782T2 (OSRAM) |
| DK (1) | DK0603305T3 (OSRAM) |
| ES (1) | ES2103966T3 (OSRAM) |
| FI (1) | FI107879B (OSRAM) |
| GR (1) | GR3024025T3 (OSRAM) |
| HK (1) | HK1021687A1 (OSRAM) |
| HU (1) | HU221006B1 (OSRAM) |
| MX (1) | MX9205240A (OSRAM) |
| NO (1) | NO941310D0 (OSRAM) |
| RO (1) | RO111991B1 (OSRAM) |
| RU (1) | RU2104010C1 (OSRAM) |
| SG (1) | SG64897A1 (OSRAM) |
| TW (1) | TW224053B (OSRAM) |
| WO (1) | WO1993005806A1 (OSRAM) |
| ZA (1) | ZA926964B (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW224053B (OSRAM) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| SG64892A1 (en) * | 1992-02-06 | 1999-05-25 | Sciclone Pharmaceuticals | Method for treating hepatitis b carriers with minimal disease |
| AU751199B2 (en) * | 1992-07-13 | 2002-08-08 | Government Of The United States Of America As Represented By The Secretary Of The Army | Composition and method of treating hepatitis B |
| EP0627930A4 (en) * | 1992-07-13 | 1997-08-20 | Kenneth E Sherman | COMPOSITION AND METHOD FOR TREATING HEPATITIS B. |
| CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| TW249754B (OSRAM) * | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
| DE69332982T2 (de) * | 1993-11-05 | 2004-09-09 | Alpha 1 Biomedicals, Inc. | Thymosin-alpha-1 enthaltende zusammensetzungen zur behandlung von hepatitis b bei patienten mit dekompensierter lebererkrankung |
| JP3837769B2 (ja) * | 1995-06-12 | 2006-10-25 | 大塚製薬株式会社 | 抗ウイルス剤 |
| GEP20012489B (en) * | 1996-02-28 | 2001-07-25 | Ifi Inst Farmacoterapico Italiano S P A | Use of Natural Human α-Interferon |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CZ301182B6 (cs) | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| ES2275711T3 (es) * | 2000-08-07 | 2007-06-16 | Sciclone Pharmaceuticals, Inc. | Tratamiento de la hepatitis c con timosina, interferon y ribavirina. |
| AU2002227252A1 (en) * | 2000-12-01 | 2002-06-11 | Cornell Research Foundation | Animal model for flaviviridae infection |
| RU2211703C2 (ru) * | 2001-06-08 | 2003-09-10 | ООО НТЦ "Юпитер-2" | Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием |
| EP1435974A4 (en) * | 2001-09-28 | 2006-09-06 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES |
| PL371683A1 (en) * | 2001-10-05 | 2005-06-27 | Intermune, Inc. | Methods of treating liver fibrosis and hepatitis c virus infection |
| CA2464795A1 (en) | 2001-10-26 | 2003-05-01 | Jack R. Wands | Thymosin augmentation of genetic immunization |
| UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| US20040002476A1 (en) * | 2002-02-14 | 2004-01-01 | Stuyver Lieven J. | Modified fluorinated nucleoside analogues |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| CN104193791A (zh) | 2002-06-28 | 2014-12-10 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
| WO2004046331A2 (en) | 2002-11-15 | 2004-06-03 | Idenix (Cayman) Limited | 2’-branched nucleosides and flaviviridae mutation |
| US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
| GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| JP4149296B2 (ja) * | 2003-03-26 | 2008-09-10 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
| KR101089145B1 (ko) | 2003-03-28 | 2011-12-02 | 사이클론 파아머슈티컬 인코오퍼레이티드 | 티모신 알파 1에 의한 아스퍼르길러스 감염의 치료 의약품 |
| CN100342907C (zh) * | 2003-03-28 | 2007-10-17 | 希克龙制药公司 | 胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用 |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| EP2345659A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| DE602004028841D1 (de) * | 2003-07-25 | 2010-10-07 | Centre Nat Rech Scient | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
| WO2005021007A1 (fr) * | 2003-08-28 | 2005-03-10 | Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' | Prevention et traitement de l'hepatite virale b |
| KR20070011451A (ko) | 2004-05-05 | 2007-01-24 | 예일 유니버시티 | 신규의 항바이러스 헬리오크산틴 유사체 |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| ES2769377T3 (es) | 2004-09-14 | 2020-06-25 | Gilead Pharmasset Llc | Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| JP5254033B2 (ja) | 2005-12-23 | 2013-08-07 | イデニク プハルマセウティカルス，インコーポレイテッド | 分岐型ヌクレオシドを調製するための合成中間体の製造方法 |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| CN101437535B (zh) * | 2006-05-02 | 2013-01-30 | 希格马托制药工业公司 | 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 |
| ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US20110195048A1 (en) * | 2008-10-08 | 2011-08-11 | Podack Eckhard R | Regulation of lymphocytes and uses therefor |
| CN102695513A (zh) | 2008-12-23 | 2012-09-26 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
| AU2009329917B2 (en) | 2008-12-23 | 2016-03-31 | Gilead Pharmasset Llc | Nucleoside analogs |
| BRPI0923815A2 (pt) | 2008-12-23 | 2015-07-14 | Pharmasset Inc | Síntese de nucleosídeos de purina |
| JP2012526149A (ja) | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| SMT201700412T1 (it) | 2010-03-31 | 2017-11-15 | Gilead Pharmasset Llc | Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| CN103800293B (zh) * | 2012-11-09 | 2015-10-21 | 长春海悦药业有限公司 | 一种含有胸腺法新的药物组合物及其制剂 |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0331934A1 (en) * | 1988-03-11 | 1989-09-13 | SCLAVO S.p.A. | New pharmaceutical compositions containing thymosin alpha 1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
| TW224053B (OSRAM) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en not_active Ceased
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 HK HK98105712A patent/HK1021687A1/en not_active IP Right Cessation
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
-
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
-
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310D0/no unknown
-
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
-
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0331934A1 (en) * | 1988-03-11 | 1989-09-13 | SCLAVO S.p.A. | New pharmaceutical compositions containing thymosin alpha 1 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU667327B2 (en) | Composition and method of treating hepatitis C | |
| HK1021687B (en) | Use of a thymosin in the treatment of hepatitis c | |
| Björkander et al. | Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency | |
| Lok et al. | Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection | |
| CA2236591C (en) | Continuous low-dose cytokine infusion therapy | |
| AU683248B2 (en) | Method of treating hepatitis C in non-responders to interferon treatment | |
| Douglas et al. | Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| WO1994001125A9 (en) | Composition and method of treating hepatitis b | |
| US6200952B1 (en) | Combination therapy method for treating chronic hepatitis B | |
| Fattovich et al. | Therapy for chronic hepatitis B with lymphoblastoid interferon‐α and levamisole | |
| Farhat et al. | Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B | |
| JPH07258109A (ja) | Ｃ型肝炎の処置法および処置用組成物 | |
| AU751199B2 (en) | Composition and method of treating hepatitis B | |
| Pockros | Current status of immunomodulatory therapies in HCV infection | |
| Ben-Noun | Interferon Therapy in Liver Cirrhosis Type C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Assignment registered |
Owner name: SCICLONE PHARMACEUTICALS, INC., THE UNITED STATES Free format text: FORMER OWNER WAS: ALPHA 1 BIOMEDICALS, INC., THE UNITED STATES OF ASMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY, THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY |